Gossamer shares take another beating as its lead drug fails 2 key clinical studies, highlighting harsh reviews for DP2
Ever since a key DP2 drug at Novartis called fevipiprant failed a pivotal lineup of clinical studies by the end of last year, a number of analysts have been sitting back waiting to see how the same kind of drug would fare at Gossamer.
Tuesday morning they found out, and it wasn’t pretty.
The biotech says their lead drug GB001 failed the primary endpoint in their dose-ranging asthma study as well as all the endpoints in a parallel trial they ran for chronic rhinosinusitis.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,100+ biopharma pros reading Endpoints daily — and it's free.